Last reviewed · How we verify
PXT3003 Intermediate Dose
At a glance
| Generic name | PXT3003 Intermediate Dose |
|---|---|
| Also known as | Pleocompound PXT3003 |
| Sponsor | Pharnext S.C.A. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |